Altravax awarded $1.2M to advance dengue vaccine and hep B therapeutic

Friday, January 11, 2013

Altravax, a privately held biopharmaceutical company based in Fargo, N.D., has been awarded two Advanced Technology Small Business Innovation Research grants from the NIH’s National Institute of Allergy and Infectious Diseases for research on vaccines to prevent infection by dengue virus and to treat chronic hepatitis B. Each of these viruses is a global problem and the focus of Altravax’s two lead commercial programs.

[Read More]